AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to “Hold”

StockNews.com downgraded shares of AC Immune (NASDAQ:ACIU) from a buy rating to a hold rating in a report released on Monday.

Separately, HC Wainwright lowered their price target on AC Immune from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 1st.

AC Immune Stock Down 0.6 %

Shares of NASDAQ:ACIU opened at $1.71 on Monday. The firm has a fifty day moving average of $1.90 and a two-hundred day moving average of $2.55. AC Immune has a 12-month low of $1.43 and a 12-month high of $4.98. The firm has a market capitalization of $171.70 million, a P/E ratio of -3.72 and a beta of 1.62.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The firm had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.99 million. Equities research analysts expect that AC Immune will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AC Immune

Several hedge funds have recently bought and sold shares of ACIU. Quinn Opportunity Partners LLC acquired a new position in shares of AC Immune during the 4th quarter valued at about $27,000. Two Sigma Advisers LP bought a new position in shares of AC Immune in the fourth quarter valued at approximately $36,000. Boothbay Fund Management LLC bought a new position in shares of AC Immune in the fourth quarter valued at approximately $38,000. RPO LLC acquired a new stake in shares of AC Immune in the fourth quarter worth $51,000. Finally, Jane Street Group LLC bought a new stake in shares of AC Immune during the 4th quarter worth $66,000. 51.36% of the stock is owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.